
Safety data sheet
Standardized safety protocols and material specifications for professional use.
Certificate of Analysis
Purity verified via High-Performance Liquid Chromatography (HPLC) for #myo-tesamorelin-10mg
Tesamorelin (10mg)
Research Grade >99% Purity
Authorized Resellers
Available through our trusted partners
123peptide.com
Netherlands · Europe
local_shipping2-3 Business Days
Depeptidenwinkel.com
Netherlands · Europe
local_shipping2-3 Business Days
Scientific Background
Intended Research Use
- Reduces visceral (abdominal) fat accumulation
- Improves lipid profiles and metabolic markers
- Supports lean muscle preservation during fat loss
- Enhances overall body composition
- May improve liver fat content in metabolic conditions
- Physiologic GH/IGF-1 elevation without broad GH side effects
menu_bookScientific Publications
J Clin Endocrinol Metab (2010)
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two phase 3 trials
open_in_newhttps://pubmed.ncbi.nlm.nih.gov/20554712/
Ann Pharmacother (2012)
Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy
open_in_newhttps://pubmed.ncbi.nlm.nih.gov/22499829/
AIDS (2013)
Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV-infected patients with abdominal fat accumulation
open_in_newhttps://pubmed.ncbi.nlm.nih.gov/23535291/
Nat Rev Endocrinol (2012)
Tesamorelin can improve cognitive function
open_in_newhttps://pubmed.ncbi.nlm.nih.gov/22945442/
FOR RESEARCH USE ONLY. This product is intended for laboratory research purposes only and is not for human consumption, medical, or diagnostic use.
Possible stacks with other peptides
Synergistic combinations for enhanced research outcomes
Tesamorelin pairs well with peptides that target complementary fat loss and metabolic pathways.

Semaglutide 5mg (5mg vial)
arrow_forwardmyo-semaglutide-5mg
Powerful dual fat-loss action — Tesamorelin boosts GH-mediated visceral fat reduction while Semaglutide provides appetite control and glycemic benefits via GLP-1 receptor activation.

Cagrilintide 5mg (5mg vial)
arrow_forwardmyo-cagrilintide-5mg
Enhanced satiety and accelerated weight loss — Cagrilintide's amylin analog action complements Tesamorelin's GH-driven lipolysis for a comprehensive metabolic protocol.

AOD-9604 5mg (5mg vial)
arrow_forwardmyo-hgh-fragment-aod-9604-5mg
Targeted lipolysis stack — AOD-9604 directly stimulates fat breakdown via GH fragment activity while Tesamorelin supports overall metabolic rate through pituitary GH stimulation.

MOTS-C 10mg (10mg vial)
arrow_forwardmyo-mots-c-10mg
Mitochondrial energy optimization meets GH-driven tissue remodeling — combining mitochondrial biogenesis support with visceral fat reduction for superior body composition outcomes.

Ipamorelin 10mg (10mg vial)
arrow_forwardmyo-ipamorelin-10mg
Selective GH secretagogue for muscle preservation — frequently combined with Tesamorelin's visceral fat reduction for comprehensive GH optimization research.

Sermorelin 5mg (5mg vial)
arrow_forwardmyo-sermorelin-acetate-5mg
Natural GHRH analog for GH/IGF-1 stimulation — studied alongside Tesamorelin for anti-aging and body composition protocols.
Cycling Note: Minimum 12 weeks; clinical evidence supports 26–52 weeks with IGF-1 monitoring. Allow 4–8 week rest between extended cycles.
